TY - JOUR AU - Wei, Ling AU - Sun, Jujie AU - Zhang, Nasha AU - Zheng, Yan AU - Wang, Xingwu AU - Lv, Liyan AU - Liu, Jiandong AU - Xu, Yeyang AU - Shen, Yue AU - Yang, Ming PY - 2020 DA - 2020/03/19 TI - Noncoding RNAs in gastric cancer: implications for drug resistance JO - Molecular Cancer SP - 62 VL - 19 IS - 1 AB - Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer. SN - 1476-4598 UR - https://doi.org/10.1186/s12943-020-01185-7 DO - 10.1186/s12943-020-01185-7 ID - Wei2020 ER -